Drug intelligence / Profile preview

NeoCast

Development stage: Unknown
Lead developer: Arsenal Medical
Administration: Intra-arterial

Overview

NeoCast is a next-generation, solvent-free, shear-responsive liquid embolic agent developed by Arsenal Medical for deep neurovascular occlusion and vessel embolization. Utilizing shear-thinning biomaterial science, the agent remains liquid during delivery through microcatheters but rapidly cures into a durable, nonadhesive elastomeric solid upon reaching the target vasculature. It is specifically designed to penetrate distal microvasculature without the use of harsh solvents or adhesives, potentially reducing procedure-related pain and inflammation. NeoCast is currently being evaluated in clinical trials for the treatment of chronic subdural hematoma (cSDH) via middle meningeal artery embolization and for the preoperative embolization of hypervascular brain tumors.

Brand names: NeoCast

Beyond the preview

Go deeper on NeoCast.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeoCast.

Explore the full profile